BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience

GeoVax Labs, Inc.

On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.
Contract covered Phase 2b clinical trial of GEO-CM04S1 COVID-19 vaccine; terminated for convenience to the government.
No financial details of termination or potential wind-down costs were disclosed in the filing.
GeoVax common stock (GOVX) and warrants (GOVXW) trade on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.